Phosphorylated Tau Levels in Donated Blood

Recruiting now

Conditions studied: Alzheimer&Amp;#39;s Disease

In brief

Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.

Key facts

Study ID

NCT07157839

Run by

The University of Texas Health Science Center, Houston

People needed

250

Starts

2025-08-28

Expected to finish

2026-11-01

Last updated by the study team

2026-02-11

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The plasma sample from donators.

You may not qualify if…

• None.

Where it is running

• University of Texas Health Science Center at Houston — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.